This Article Free Full Text Free Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Therrien, J.-P. Articles by Vogel, J. C. Search for Related Content PubMed PubMed Citation Articles by Therrien, J.-P. Articles by Vogel, J. C. Pubmed/NCBI databases Medline Plus Health Information Genes and Gene Therapy Social Bookmarking                         What's this?

An Approach to Achieve Long-Term Expression in Skin Gene Therapy

¹ Dermatology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA
² Department of Dermatology and Allergology, Philipps-University, Marburg, Germany

Correspondence: Address correspondence to: Jean-Philippe Therrien, PhD, Dermatology Branch, National Cancer Institute, NIH, Bldg. 10/Room 12N254, 10 Center Drive MSC 1908, Bethesda, MD 20892-1908; e-mail: therriej{at}mail.nih.gov.

For gene therapy purposes, the skin is an attractive organ to target for systemic delivery of therapeutic proteins to treat systemic diseases, skin diseases, or skin cancer. To achieve long-term stable expression of a therapeutic gene in keratinocytes (KC), we have developed an approach using a bicistronic retroviral vector expressing the desired therapeutic gene linked to a selectable marker (multidrug resistant gene, MDR) that is then introduced into KC and fibroblasts (FB) to create genetically modified human skin equivalent (HSE). After grafting the HSE onto immunocompromised mice, topical colchicine treatment is used to select and enrich for genetically modified keratinocyte stem cells (KSC) that express MDR and are resistant to colchicine’s antimitotic effects. Both the apparatus for topical colchicine delivery and the colchicine doses have been optimized for application to human skin. This approach can be validated by systemic delivery of therapeutic factors such as erythropoietin and the antihypertensive atrial natriuretic peptide.

Key Words: Human skin • gene therapy • multidrug resistance gene • bicistronic retroviral vectors • systemic delivery • topical selection

Abbreviations: ANP, atrial natriuretic peptide • DNA, deoxyribonucleic acid • FACS, flow activated cell sorting • FB, fibroblast • H&E, hematoxylin and eosin • HSE, human skin equivalent • JEB, junctional epidermolysis bullosa • KC, keratinocyte • KSC, keratinocyte stem cell • MDR, multi-drug resistance gene • MFI, mean fluorescence intensity • TA, transient amplifying cell • TNF-, tumor necrosis factor-alpha

Toxicologic Pathology, Vol. 36, No. 1, 104-111 (2008)
DOI: 10.1177/0192623307312705


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?